Extensive immunohistochemical analysis of Ang-2 with three frequently reported commercial Ang-2 antibodies produced ambiguous results concerning the tissue localisation in human CRC because of poor antibody specificity (Supplementary Figure 1).
Controversy concerning the subcellular localisation of the BRCA1 protein has abounded, with it being reported as nuclear (Scully et al, 1996), nuclear in normal but cytoplasmic in breast and ovarian carcinoma cells (Chen et al, 1995), membrane associated on the cytoplasmic aspect of nuclear invaginations (Coene et al, 1997), or a secreted growth inhibitor (Holt et al, 1996; Jensen et al, 1996).
As S100A9 acts as a chemo-attractant for certain immunosuppressive cells and is expressed in myeloid suppressor cells that are important in diseases such as cancer (Ostrand-Rosenberg and Sinha, 2009), we decided to perform a deeper analysis concerning the expression and localisation pattern of S100A9 and its correlation to the presence of different tumour-infiltrating myeloid cells.
Another controversial issue concerns the nuclear cytoplasmic localisation of c-Myc.
A key observation concerns the dynamic localisation of eIF2B in response to alcohols (Taylor et al., 2010).
At present, there is no information concerning the expression of NrCAM (gene or protein), its cellular localisation and distribution, or its role in the evolution of thyroid papillary carcinomas.
Yet, there is a limitation in our work: the absence of functional studies concerning the potential effects of these novel MC1R variants, notably on α-MSH binding, receptor cellular localisation, and cAMP signalling.
Together, these studies associated differential expression and localisation of cyclin D1 with important clinicopathological parameters and suggest new insight concerning the potential consequence of cyclin D1 induction in prostate cancer.
